{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:54Z","timestamp":1791331254673,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01526-7","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:06:27Z","timestamp":1779955587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuji","family":"Mino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoharu","family":"Takeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-1550","authenticated-orcid":false,"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-5824","authenticated-orcid":false,"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-4757","authenticated-orcid":false,"given":"Takuya","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Io","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-4470","authenticated-orcid":false,"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-812X","authenticated-orcid":false,"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-278X","authenticated-orcid":false,"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-6208","authenticated-orcid":false,"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"1526_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"1526_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"1526_CR3","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","volume":"8","author":"K Murai","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8:e902\u2013e911.","journal-title":"Lancet Haematol"},{"key":"1526_CR4","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"1526_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK-25-473082","volume":"45","author":"N Shanmuganathan","year":"2025","unstructured":"Shanmuganathan N, Osborn M, Hughes TP. Which is the best tyrosine kinase inhibitor for newly diagnosed chronic myelogenous leukemia?. Am Soc Clin Oncol Educ Book. 2025;45:1\u201312.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1526_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"1526_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"1526_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"1526_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.2020005514","volume":"137","author":"N Shanmuganathan","year":"2021","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137:1196\u2013207.","journal-title":"Blood"},{"key":"1526_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41375-018-0055-7","volume":"32","author":"S Saussele","year":"2018","unstructured":"Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, et al. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia. 2018;32:1222\u20138.","journal-title":"Leukemia"},{"key":"1526_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106273","volume":"88","author":"H Ureshino","year":"2020","unstructured":"Ureshino H, Shindo T, Kimura S. Role of cancer immunology in chronic myelogenous leukemia. Leuk Res. 2020;88:106273.","journal-title":"Leuk Res"},{"key":"1526_CR13","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121:3818\u201324.","journal-title":"Blood"},{"key":"1526_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11030438","volume":"11","author":"J Chauhan","year":"2022","unstructured":"Chauhan J, Stavraka C, Grandits M, Palhares LCGF, Josephs DH, Lacy KE, et al. Clinical and translational significance of basophils in patients with cancer. Cells. 2022;11:1\u201319.","journal-title":"Cells"},{"key":"1526_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","volume":"17","author":"JE Cortes","year":"2017","unstructured":"Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk. 2017;17:78\u201382.","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01526-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:06:28Z","timestamp":1779955588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01526-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01526-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HU has received honoraria from Novartis. Takashi K. has received honoraria from Bristol-Myers Squibb and Novartis. KN has received honoraria from Novartis, Argenx Japan, and Alexion Pharmaceuticals. CY has received honoraria from Novartis, Pfizer, and Otsuka Pharmaceutical, and research funding from Bristol-Myers Squibb. NU has received honoraria from Johnson & Johnson and Bristol-Myers Squibb. JK serves as a consultant for Janssen Pharmaceutical, AbbVie, Pfizer, BeOne Medicines, Genmab, and Bristol-Myers Squibb; has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Japan Blood Products Organization, and Asahi Kasei; and has received honoraria from Janssen Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, Bristol-Myers Squibb, Novartis, AbbVie, Pfizer, BeOne Medicines, Genmab, and Astellas Pharma. Takeshi K. has received honoraria from AbbVie, Astellas Pharma, Bristol-Myers Squibb, Daiichi Sankyo, GSK, Nippon Shinyaku, Novartis Pharma, Otsuka Pharmaceutical, and Pfizer, and research funding from Novartis Pharma and Ohara Pharmaceutical. Takuya M. has received honoraria from Chugai Pharmaceutical, Astellas Pharma, and Novartis Pharma. TU has received honoraria from Chugai Pharmaceutical. TO has received honoraria from Otsuka Pharmaceutical, Pfizer Japan, and Novartis Pharma. KU has received research funding from Agios, Alexion, Aperis, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Gilead, Incyte, Kyowa Kirin, Nippon Shinyaku, Novartis Pharma, Ohara Pharmaceutical, Ono Pharmaceutical, Otsuka Pharmaceutical, PharmaEssentia, Sanofi, and Takeda, and has participated in speaker bureau activities for AbbVie, Amgen, Asahi Kasei Pharma, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Genmab, Incyte, Kyowa Kirin, Nippon Shinyaku, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sandoz, and Takeda. TY has received honoraria from AbbVie, Nippon Shinyaku, and Sumitomo Pharma. TI has received honoraria from Bristol-Myers Squibb, Novartis Pharma, Pfizer, Takeda, AbbVie, Otsuka Pharmaceutical, Daiichi Sankyo, Asahi Kasei Pharma, Alexion, Chugai Pharmaceutical, Sanofi, Astellas Pharma, and Nippon Shinyaku Co., Ltd., and has received research funding from AbbVie, Alexion, Sanofi, Pfizer, and Amgen. S.K. has received honoraria from Novartis, Pfizer, and Otsuka Pharmaceutical, and research funding from Novartis Pharma and Ohara Pharmaceutical. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of Saga University as well as the institutional review boards of all participating centers (approval number:\n                      2024-07-04\n                      ). The original DAVLEC study was registered with the UMIN Clinical Trials Registry (\n                      UMIN000024548\n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"83"}}